The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small-cell lung cancer (NSCLC): A phase II clinical trial.
 
Yuichi Ozawa
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
 
Kazuhisa Nakashima
No Relationships to Disclose
 
Haruko Daga
Honoraria - Chugai/Roche; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai/Roche (Inst); Lilly (Inst)
 
Hisao Imai
No Relationships to Disclose
 
Motohiro Tamiya
Honoraria - Asahi Kasei; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Ono Pharmaceutical
 
Takaaki Tokito
Honoraria - AstraZeneca; Chugai Pharma; MSD
 
Takahisa Kawamura
No Relationships to Disclose
 
Hiroaki Akamatsu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - MSD (Inst)
 
Yuko Tsuboguchi
No Relationships to Disclose
 
Toshiaki Takahashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; Merck Sharp & Dohme; Ono Pharmaceutical; Pfizer; Roche
Research Funding - AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Maruho (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); TERUMO (Inst); Toppan Printing Co. (Inst); Tosoh Corporation (Inst); Tsumura & Co. (Inst)
 
Keita Mori
No Relationships to Disclose
 
Haruyasu Murakami
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); IQvia (Inst); Lilly Japan (Inst); Takeda (Inst)